On one hand, administration of PD-1/PD-L1 blockade prior to RT may lead to re-invigoration of exhausted tumor-infiltrating T-cells, or prevention of exhaustion of newly infiltrating T-cells, with potentiation of radiation-mediated killing by T-cell response. The gene discussed is CD274; the disease is neoplasm.